At the time of writing, Fate Therapeutics Inc [FATE] stock is trading at $1.34, up 1.52%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The FATE shares have gain 6.77% over the last week, with a monthly amount drifted -20.47%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Fate Therapeutics Inc [NASDAQ: FATE] stock has seen the most recent analyst activity on November 18, 2024, when BofA Securities upgraded its rating to a Neutral. Previously, Piper Sandler upgraded its rating to Overweight on June 17, 2024, and elevated its price target to $6. H.C. Wainwright downgraded its rating to a Neutral and decreased its price target to $7 on January 24, 2023. Wedbush downgraded its rating to a Neutral and reduced its price target to $7 on January 06, 2023. Truist downgraded its rating to Hold for this stock on January 06, 2023, and downed its price target to $7. In a note dated January 06, 2023, Stifel downgraded an Hold rating on this stock and revised its target price from $107 to $5.30.
For the past year, the stock price of Fate Therapeutics Inc fluctuated between $1.04 and $8.83. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Fate Therapeutics Inc [NASDAQ: FATE] shares were valued at $1.34 at the most recent close of the market. An investor can expect a potential return of 273.13% based on the average FATE price forecast.
Analyzing the FATE fundamentals
According to Fate Therapeutics Inc [NASDAQ:FATE], the company’s sales were 13.45M for trailing twelve months, which represents an 58.13% jump. Gross Profit Margin for this corporation currently stands at -2.3% with Operating Profit Margin at -14.62%, Pretax Profit Margin comes in at -13.25%, and Net Profit Margin reading is -13.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.46 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2900 points at the first support level, and at 1.2400 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3800, and for the 2nd resistance point, it is at 1.4200.
Ratios To Look Out For
It is important to note that Fate Therapeutics Inc [NASDAQ:FATE] has a current ratio of 8.29. Further, the Quick Ratio stands at 8.29, while the Cash Ratio is 1.01. Considering the valuation of this stock, the price to sales ratio is 11.35, the price to book ratio is 0.42.
Transactions by insiders
Recent insider trading involved Bressi Jerome Charles,, that happened on Jan 10 ’25 when 5980.0 shares were sold., TAHL CINDY completed a deal on Jan 10 ’25 to sell 5654.0 shares. Meanwhile, President and CEO Valamehr Bahram sold 8705.0 shares on Jan 10 ’25.
